Should you buy Catalyst Biosciences stock? (NasdaqCM:CBIO). Let's see how it does in our automated value investing analysis system.
(Catalyst Biosciences stock price per share)
|PE Ratio versus Sector||100% lower than other Healthcare stocks|
|PE Ratio versus Industry||100% lower than other Biotechnology stocks|
|Free Cash Flow Jitter||44%|
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 531,450 shares shorted. With 25,158,979 shares available for purchase and an average trading volume over the past 10 trading days of 310,360, it would take at least 1.712 days for all of the short holders to cover their shorts.
Based on our analysis, we believe that you should not buy Catalyst Biosciences right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.
Does Catalyst Biosciences have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles
How to Invest $1000 in the Stock Market
How Do Stock Brokers Make Money?
What are The Dow, S&P 500, and NASDAQ Indexes?
What Happened to the Stock Market Today?
The Current Price of Silver Today
Should You Invest in Gold or Silver?
Why Do Companies Pay Dividends?
How to Make Money with Penny Stocks
How Does Social Distancing Affect the Economy?